News
Novartis announces positive results from VAYHIT2 phase III trial of ianalumab plus eltrombopag in patients with primary immune thrombocytopenia: Basel Wednesday, August 13, 2025, ...
Yantai-based RemeGen said it will now move ahead with filing telitacicept with China's National Medical Products ...
The China-based phase 3 trial of telitacicept in primary Sjögren's syndrome (pSS) met its primary endpoint, which focused on ...
J.P. Morgan analyst Richard Vosser maintained a Hold rating on Novartis AG today and set a price target of CHF95.00. The company’s shares opened today at CHF96.08. Take advantage of TipRanks Premium ...
Vor Bio shares climb as RemeGen's Phase 3 study in China shows telitacicept improves disease activity in primary Sjögren's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback